Extreme Movers: Grok 4.5's picks for 2026-10-12
Grok 4.5 picked CCI, MRNA, HUM, TMUS, T for a 1-day horizon. Average directional return: -1.30%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | Grok 4.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -1.30% |
| Directions called correctly | 40% |
| Benchmark return | -0.06% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | CCI | up | +1.72% | +1.72% | 68% | +1.78% | Yes |
| 2 | MRNA | up | -5.00% | -5.00% | 62% | -4.94% | No |
| 3 | HUM | up | +0.38% | +0.38% | 65% | +0.44% | Yes |
| 4 | TMUS | down | +2.21% | -2.21% | 60% | -2.15% | No |
| 5 | T | down | +1.40% | -1.40% | 58% | -1.34% | No |
The model's market view
Friday's session closed higher across major indices amid a mixed sector picture. Wireless tower REITs surged on the SpaceX spectrum acquisition news, which investors viewed as a net positive for infrastructure demand, while the three major US wireless carriers sold off sharply on competition concerns. Biotech and managed-care names advanced on vaccine-related reports and improved Medicare Advantage star ratings. Liquidity was strong in the large-cap names that led the extremes, setting up a weekend digestion of the catalyst before Monday's open.
Why each pick
CCI
Crown Castle led S&P 500 gainers with a +15.60 percent move on the SpaceX spectrum deal, which is a substantive catalyst because it signals potential incremental tower leasing demand from a new national tenant. Ranking prioritizes the cleanest large-cap infrastructure beneficiary with confirmed volume and market-cap floors. Hypothesis is continuation higher as the deal details continue to be digested; main risk is profit-taking or any clarification that reduces near-term lease upside. Reference price is the regular-session close of 9 October; no fresher quote available on the weekend.
MRNA
Moderna rose 14.21 percent on reports of an NIH cancer-vaccine push and related trial momentum, a catalyst that is partly substantive (ongoing oncology data) and partly speculative (policy headlines). Ranking reflects the magnitude of the move, ample liquidity, and clear market-cap qualification. Continuation higher is favored on momentum into the next session; risk is that the move was front-loaded and fades without new data. Price used is the 9 October regular close.
HUM
Humana gained 11.56 percent after CMS improved its Medicare Advantage star ratings, a substantive regulatory catalyst that directly affects bonus payments and margins. Ranking places it after the pure infrastructure and biotech leaders but ahead of the carriers because the catalyst is company-specific and durable. Continuation is expected as the rating impact is quantified; risk is any broader managed-care rotation. Reference price is the 9 October close.
TMUS
T-Mobile fell 13.27 percent on the same SpaceX spectrum deal that lifted the tower names, reflecting investor concern over satellite competition; the catalyst is substantive in origin but speculative in the magnitude of near-term share-loss assumptions. Ranking reflects the largest absolute carrier decline with full liquidity and size qualification. Continuation lower is the base case while the competitive narrative remains unresolved; risk is a quick rebound if management commentary or further deal details calm fears. Price is the 9 October regular close.
T
AT&T declined 9.81 percent in sympathy with the other wireless carriers on SpaceX competition headlines, a largely speculative read-through given the company's scale and existing spectrum position. Ranking is last among the five because the move was smaller than TMUS yet still meets every liquidity and size filter. Continuation lower is favored while the sector remains under pressure; risk is mean-reversion given the stock's high dividend and defensive characteristics. Reference price is the 9 October close.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | LITE, CIEN, HUM, T, FSLY | -1.63% | 60% |
| GPT-6 | TMUS, HUM, CCI, AMT, ASTS | +0.33% | 60% |
| Perplexity | HUM, TMUS, T, CCI, ASTS | +0.26% | 60% |
| Gemini 1.5 Pro | CCI, HUM, MRNA, TMUS, DDOG | -0.62% | 60% |
| DeepSeek | FSLY, NVAX, TMUS, HUM, ALHC | -3.63% | 40% |
| Claude Sonnet 5.5 | HUM, MRNA, TMUS, CCI, FSLY | +3.13% | 80% |
Written up on ForecastNest Insights: Extreme Movers: Grok 4.5's picks for 2026-10-12.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.